FoRx Therapeutics AG
DNA Replication Stress for Cancer (DRS) pathways
FoRx Therapeutics is a recently incorporated privately-held company based in Basel, Switzerland. It is backed by a syndicate of investors that include the Novartis Venture Fund, Pfizer Ventures, M Ventures, Omega Funds and LSP Venture Capital. FoRx Therapeutics focuses on drugging key molecular targets involved in the DNA Replication Stress, as a new approach in the development of targeted anticancer drugs.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
11.08.2025
Two biotech start-ups significantly closer to market (startupticker.ch)
22.04.2021
Senior leadership appointments at fintech and pharma startups (startupticker.ch)
22.04.2020
Basel-based FoRx Therapeutics secures EUR 10 million seed round (startupticker.ch)
No milestones
No Jobs
No videos and documents
FoRx Therapeutics AG
DNA Replication Stress for Cancer (DRS) pathways
Website:
forxtherapeutics.com/
Headquarter:
Basel
Foundation Date:
October 2019
Technology:
- Biotech
Sectors:
- Biotech
- Cancer